Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-15
2008-04-15
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000
Reexamination Certificate
active
07358228
ABSTRACT:
The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
REFERENCES:
patent: 4883666 (1989-11-01), Sabel et al.
patent: 5084350 (1992-01-01), Chang et al.
patent: 5284761 (1994-02-01), Aebischer et al.
patent: 5496804 (1996-03-01), Reed et al.
patent: 5618531 (1997-04-01), Cherksey
patent: 5733729 (1998-03-01), Lipshutz et al.
patent: 5754524 (1998-05-01), Wark
patent: 5795716 (1998-08-01), Chee et al.
patent: 5800992 (1998-09-01), Fodor et al.
patent: 5834029 (1998-11-01), Bellamkonda et al.
patent: 5916555 (1999-06-01), Lee et al.
patent: 6593133 (2003-07-01), Johansen et al.
patent: 6734284 (2004-05-01), Johansen et al.
patent: 2004/0242472 (2004-12-01), Shelton et al.
patent: 2005/0181991 (2005-08-01), Shelton et al.
patent: WO 93/06116 (1993-04-01), None
patent: WO 97/08196 (1997-03-01), None
patent: WO 97/11964 (1997-04-01), None
patent: WO 98/32869 (1998-07-01), None
patent: WO 99/49039 (1999-09-01), None
patent: WO 00/01815 (2000-01-01), None
patent: WO 00/04050 (2000-01-01), None
patent: WO 00/18799 (2000-04-01), None
patent: WO 00/34475 (2000-06-01), None
patent: WO 00/73348 (2000-12-01), None
patent: WO 02/051433 (2002-07-01), None
patent: WO 02/060929 (2002-08-01), None
patent: WO 02/078730 (2002-10-01), None
Sah et al. Society for Neuroscience Abstracts 27(1):361, 2001.
Kim Sh et al. Pain 50:355-363, 1992.
Wang Lx et al. Advanced Drug Delivery Reviews 55:949-965, 2003.
Airaksmen et al. (1999), GDNF family neurotrophic factor signaling: four masters, one servant,Mol Cell Neurosci, 13:313-325.
Atschul et al. (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,”Nucl. Acids Res., 25:3389-3402.
Baloh et al. (1998), “Artemm, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex,”Neuron, 21:1291-1302.
Borodovsky et al. (1995), “Detection of new genes in a bacterial genome using Markov models for three gene classes,”Nucl. Acids Res., 23:3554-3562.
Daopin et al. (1993), “Chrystal structure of TGF-β2 refined at 1.8 A resolution,”Proteins, 17:176-192.
Eigenbrot and Gerber (1997), “X-ray structure of glial cell-derived neurotrophic factor at 1 9 A resolution and implications for receptor binding,”Nat. Struct. Biol., 4:435-438.
Finsen et al. (1992), “Somatostatin and neuropeptide Y in organotypic slice cultures of the rat hippocampus: an immunocytochemical and in situ hybridization study,”Neurosci, 47:105-113.
GenBank Accession AA844072 (Dec. 31, 1998).
Lapchak (1977), “Therapeutic potential for glial cell line-derived neurotropic factor (GDNF) based upon pharmacological activities in the CNS,”Rev. Neurosci., 7:165-176).
Lapchak et al. (1996), “Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases,”Cell Tissue Res., 286:179-189.
Lin et al. (1993), GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons,Science, 260:1130-1132.
Lorenz et al. (1996), “Heteromultimeric CLC chloride channels with novel properties,”Proc. Natl. Acad. Sci USA, 93: 13362-13366.
Massague et al. (1994), “The TGF-β family and its composite receptor,”Trends Cell Biol., 4:172-178.
Masure et al. (1999), “Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells,”Eur. J. Biochem, 266:892-902.
McDonald and Hendrickson (1993), “A structural superfamily of growth factors containing a cystine knot motif.,”Cell, 73:421-424.
Milbrandt et al. (1998), Persephin, a novel neurotrophic factor related to GDNF and neurturin,Neuron, 20:245-253.
Robertson and Manson (1997), “The GDNF-RET signaling in partnership,”Trends Genet., 13:1-3.
Saarma and Sariola (1999),Microscopy Res. &Technique, 45:292-302.
Sanicola et al. (1997), “Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins,”Proc Natl Acad Sci USA, 94:6238-6243.
Sauer and Oertel (1994), “Progressive degeneration of nigrostriatal dopamine neurons following intrastraiatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat,”Neuroscience, 59:401-415.
Slooth and Gramsbergen (1995), “Detection of salicylate and its hydroxylated adducts 2.3- and 2.5- dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissue,”J. Neurosci. Meth., 60:141-149.
Stoppini et al. (1991), “A simple method for organotypic cultures of nervous tissue,”J. Neurosci. Methods, 37:173-182.
Thompson et al. (1997), “The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools,”Nucl. Acids Res., 25:4876-4882.
Unsicker (1996), “GDNF: a cytokine at the interface of TGF-betas and neurotrophins,”Cell Tissue Res., 286:175-178.
Von Schwedler et al. (1993), “Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells,”J. Virol., 67:4945-4955.
Zufferey et al. (1997), “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,”Nat. Biotechnol., 15:871-875.
Gardell et al. (2003) “Multiple actions of systemic artemin in experimental neuropathy” Nat Med. 2003 9(11):1383-89.
Orozco et al., Society for Neuroscience Abstracts 26 (1-2): Abstract No. 412.7, 2000.
Johansen Teit E.
Rossomando Anthony
Sah Dinah W. Y.
Biogen Idec MA Inc.
Fish & Richardson P.C.
Landsman Robert
NsGene A/S
LandOfFree
Methods of treating pain using neurotrophic factors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating pain using neurotrophic factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating pain using neurotrophic factors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2779975